KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Net Cash Flow (2016 - 2026)

Neogenomics filings provide 17 years of Net Cash Flow readings, the most recent being -$13.5 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow rose 35.27% to -$13.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$200.1 million, a 1500.92% decrease, with the full-year FY2025 number at -$207.4 million, down 945.68% from a year prior.
  • Net Cash Flow hit -$13.5 million in Q1 2026 for Neogenomics, down from -$4.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $36.2 million in Q4 2023 to a low of -$191.4 million in Q2 2025.
  • Median Net Cash Flow over the past 5 years was -$2.9 million (2022), compared with a mean of -$10.0 million.
  • Biggest five-year swings in Net Cash Flow: soared 1330.45% in 2023 and later plummeted 926.11% in 2025.
  • Neogenomics' Net Cash Flow stood at -$2.9 million in 2022, then soared by 1330.45% to $36.2 million in 2023, then tumbled by 86.15% to $5.0 million in 2024, then tumbled by 190.26% to -$4.5 million in 2025, then crashed by 197.4% to -$13.5 million in 2026.
  • The last three reported values for Net Cash Flow were -$13.5 million (Q1 2026), -$4.5 million (Q4 2025), and $9.4 million (Q3 2025) per Business Quant data.